Neurocrine Expands Crinecerfont Trials into Younger Pediatric CAH Patients
Event summary
- Neurocrine Biosciences initiated a Phase 2 study of crinecerfont in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH).
- The open-label, single-arm study will enroll 20 participants and run for 24 weeks.
- Crinecerfont is currently approved for patients aged 4 and older; this trial aims to expand its use to younger patients.
- Neurocrine also achieved target enrollment for a separate Phase 2 study in the EU for children from birth to under 2 years old with CAH.
The big picture
Neurocrine's expansion into younger pediatric patients with CAH reflects a strategic push to address an unmet need in rare disease treatment. The company is leveraging its existing approval for crinecerfont to potentially dominate the CAH market, which has seen no therapeutic advancements in over 70 years. Success in these trials could solidify Neurocrine's position as a leader in endocrine and metabolic disorders.
What we're watching
- Regulatory Pathway
- Whether the Phase 2 data will support a supplemental New Drug Application to expand crinecerfont's approved indication to include patients under 4 years old.
- Clinical Efficacy
- How crinecerfont performs in reducing glucocorticoid use and mitigating associated risks in this younger patient population.
- Market Opportunity
- The pace at which Neurocrine can establish crinecerfont as a standard treatment for CAH across all age groups, given the lack of approved therapies for children under 4.